Centessa Extends ORX750 Narcolepsy Study: What Investors Should Watch Now

Centessa Pharmaceuticals Plc (CNTA) announced an update on their ongoing clinical study.

The Phase 2 long term extension study NCT07096674 follows patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia who finished an earlier ORX750 trial. It aims to track long term safety, side effects, and how well the drug keeps working, giving investors a clearer view of the durability of Centessa’s sleep disorder franchise.

The study tests ORX750, an oral drug being developed by Centessa Pharmaceuticals (UK) Ltd. The goal is to reduce excessive daytime sleepiness and related symptoms over time, offering a potential new option in a market now led by drugs like Xywav and Wakix.

This is an interventional Phase 2 trial with a single treatment group, so all enrolled patients receive ORX750. There is no placebo and no blinding, which makes this an open label study focused on practical treatment use rather than strict head to head comparisons.

Allocation is non randomized, reflecting that only prior ORX750 trial completers can join. The primary purpose is treatment, so the key readouts center on safety and sustained benefit, data that regulators and potential commercial partners will watch closely.

The sponsor first submitted the study on July 2, 2025, marking the formal start of the long term program in ORX750. The trial remains in the recruiting phase, signaling that enrollment and site ramp up are still underway.

The most recent update to the record was filed on March 18, 2026, confirming the study status and design. No results have been posted yet, so investors should view this as a pipeline progress marker rather than an efficacy or risk inflection point.

For Centessa Plc (CNTA), progress in this extension study supports the core thesis that ORX750 can drive a durable sleep disorder franchise. Positive long term data could boost confidence in peak sales potential and help narrow the valuation gap to established players in narcolepsy and idiopathic hypersomnia.

Competitors such as Jazz Pharmaceuticals and Harmony Biosciences already serve this space, but an effective oral therapy with a strong safety record could carve out share. Until actual data arrive, the update mainly underpins sentiment that the program is active and advancing rather than changing the risk reward balance.

The ORX750 long term extension trial for narcolepsy and idiopathic hypersomnia is ongoing and has been recently updated, with more details available on the ClinicalTrials portal.

To learn more about CNTA’s potential, visit the Centessa Pharmaceuticals Plc drug pipeline page.